Madeddu P, Parpaglia P P, Glorioso N, Chao L, Chao J
Clinica Medica, University of Sassari, Italy.
Hypertension. 1996 Dec;28(6):980-7. doi: 10.1161/01.hyp.28.6.980.
We used antisense oligodeoxynucleotide (ODN) strategy, based on interference of information flow from gene to protein, to determine the role of kininogen and bradykinin B2 receptor genes in the pathogenesis of genetic hypertension in rats. Mean blood pressure of 9-week-old spontaneously hypertensive rats (SHR) increased 4 hours after acute intracerebroventricular injection of synthetic 18-mer antisense ODNs targeting the translation initiation codon of kininogen mRNA (from 164 +/- 5 to 181 +/- 4 mm Hg, P < .01) or bradykinin B2 receptor mRNA (from 161 +/- 5 to 185 +/- 8 mm Hg, P < .01) and then returned to basal levels within 24 hours. Prolonged vasopressor effects were observed after repeated injections of antisense ODN targeting kininogen mRNA. Antisense ODNs to kininogen and B2 receptor mRNAs increased blood pressure of normotensive Wistar-Kyoto rats only slightly compared with SHR (from 116 +/- 3 to 124 +/- 1 and from 116 +/- 2 to 126 +/- 4 mm Hg, respectively; P < .05). Cardiovascular responses were confirmed by the use of antisense ODNs targeted to bind to different non-overlapping regions of kininogen or B2 receptor mRNA. Microinjection of antisense ODN to B2 receptor mRNA into the nucleus tractus solitarii increased mean blood pressure in SHR and prevented the vasodepressor effect induced by intranuclear microinjection of bradykinin. No significant change in mean blood pressure was induced in either strain by intravenous injection of antisense ODNs or by central injection of sense or scrambled ODNs. A strong fluorescent signal was detected at the level of the hippocampus, thalamus, hypothalamus periventricularis, midbrain, and cerebrum 1 hour after central injection of fluorescein isothiocyanate-conjugated antisense ODNs. Kininogen levels were significantly lower in the brain of rats given intracerebroventricular antisense kininogen ODN compared with controls. Our results indicate that the brain kallikrein-kinin system plays a role in the central regulation of blood pressure and suggest that this system may exert a protective action against further elevations of blood pressure levels in SHR.
我们采用反义寡脱氧核苷酸(ODN)策略,基于对基因到蛋白质信息流的干扰,来确定激肽原和缓激肽B2受体基因在大鼠遗传性高血压发病机制中的作用。急性脑室内注射针对激肽原mRNA翻译起始密码子的合成18聚体反义ODN(收缩压从164±5升高至181±4 mmHg,P<.01)或缓激肽B2受体mRNA的反义ODN(收缩压从161±5升高至185±8 mmHg,P<.01)4小时后,9周龄自发性高血压大鼠(SHR)的平均血压升高,然后在24小时内恢复至基础水平。重复注射针对激肽原mRNA的反义ODN后观察到持续的升压效应。与SHR相比,激肽原和B2受体mRNA的反义ODN仅使正常血压的Wistar-Kyoto大鼠血压略有升高(分别从116±3升高至124±1和从116±2升高至126±4 mmHg;P<.05)。通过使用靶向结合激肽原或B2受体mRNA不同非重叠区域的反义ODN,证实了心血管反应。向孤束核微量注射B2受体mRNA的反义ODN可使SHR平均血压升高,并阻止核内微量注射缓激肽诱导的降压效应。静脉注射反义ODN或中枢注射正义或乱序ODN均未在两种品系中引起平均血压的显著变化。中枢注射异硫氰酸荧光素偶联的反义ODN 1小时后,在海马、丘脑、下丘脑室周区、中脑和大脑水平检测到强荧光信号。与对照组相比,脑室内给予反义激肽原ODN的大鼠脑中激肽原水平显著降低。我们的结果表明,脑激肽释放酶-激肽系统在血压的中枢调节中起作用,并提示该系统可能对SHR血压水平的进一步升高发挥保护作用。